Gargi Dwivedi, MD
Family Medicine · Phoenix, AZNPI 1700874153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Bayer at 27.6% of the total. 2025 is the largest year on record at $740, more than ten times the $48 reported in 2019.
Across 24 payments — averaging $49.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$327
- Novo Nordisk$155
- Intra-sana Laboratories$153
- Amgen$150
- AstraZeneca$103
- Sanofi-aventis U.S. LLC$44
- plus $253 from 10 others
What the payments were for
- Food & beverage$1,185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $327 |
| Novo Nordisk | 3 | $155 |
| Intra-sana Laboratories | 2 | $153 |
| Amgen | 1 | $150 |
| AstraZeneca | 1 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| Exact Sciences | 2 | $43 |
| Indivior Inc. | 1 | $43 |
| Abbott | 3 | $43 |
| Alkermes, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Nalu Medical, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$327
- TEPEZZA$150
- Reltone 200 Mg$147
- GLYCATE$147
- Reltone 400 Mg$147
- Wegovy$104
- FARXIGA$103
How this compares
$1,185 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $316 |
| Atorvastatin Calcium | 16 | $241 |
| Levothyroxine Sodium | 33 | $237 |
| Fluticasone Propionate | 13 | $220 |
| Metoprolol Succinate | 12 | $215 |
| Gabapentin | 13 | $156 |
| Metformin Hcl | 11 | $112 |
| Amlodipine Besylate | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Phoenix
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Randy GelowPhoenix$56K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.